Andreas Ziebart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andreas Ziebart has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Mayer
Institute of Epidemiology and Medical Biometry, Ulm University, Germany
3 shared publications Christian Rainer Wirtz
3 shared publicationsAli Karakoyun
Department of Neurosurgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
2 shared publicationsAndrej Pala
2 shared publicationsAssel Saryyeva
Department of Neurosurgery, Hannover Medical School, MHH, Hannover, Germany
2 shared publications- Dumitru Ciolac
Department of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Elsevier in Brain and Spine
- Vol. 6
Longitudinal volume evolution of large and giant intracranial aneurysms following endovascular flow diversion
- 23 July 2026
- Published by Elsevier in Brain and Spine
- Vol. 6
Open AccessLongitudinal volume evolution of large and giant intracranial aneurysms following endovascular flow diversion
- 8 May 2026
- Vol. 150, 112077
Influence of the correct placement of external ventricular drainage on puncture channel bleeding in patients with aneurysmal subarachnoid hemorrhage.
While ventriculostomy-associated hemorrhages are well-documented in spontaneous subarachnoid hemorrhage (SAH), the impact of external ventricular drainage (EVD) placement accuracy on puncture channel bleeding (PCB) remains underexplored. This study investigates whether incorrect EVD trajectory is associated with increased PCB risk in aneurysmal SAH (aSAH) patients and evaluates the influence of peri-interventional antiplatelet and anticoagulation therapy on these events. We analyzed 127 patients with aSAH who underwent EVD placement and aneurysm treatment between September 2021 and June 2025 from our prospectively maintained registry. EVD positioning was classified as correct (ipsilateral intraventricular) or incorrect (e.g., contralateral or intraparenchymal). PCB was defined as hemorrhage along the catheter tract on post-procedural CT. Data on antiplatelet/anticoagulant use and clinical outcomes were collected. Functional and cognitive outcomes were assessed using the modified Rankin Scale (mRS) and Montreal Cognitive Assessment (MoCA), respectively. PCB occurred in 20% of patients. Incorrect EVD placement was strongly associated with PCB, occurring in 56% of malpositioned catheters compared with 15% of correctly positioned catheters (p < 0.001). In multivariable logistic regression, incorrect EVD placement remained the only independent predictor of PCB (OR 7.8, 95% CI 2.45-26.35; p < 0.001). Neither pre-admission antiplatelet or anticoagulation therapy nor peri-interventional antiplatelet therapy was significantly associated with PCB (all p = 0.5). In univariate analysis, functional outcome at discharge and at 3 months did not significantly differ between groups (p = 0.43 and p = 0.28, respectively). However, in multivariable analysis adjusting for age and clinical severity, PCB was independently associated with a lower likelihood of favorable functional outcome both at discharge (OR 0.19, 95% CI 0.04-0.70; p = 0.02) and at 3 months (OR 0.10, 95% CI 0.01-0.75; p = 0.03). Cognitive outcome (MoCA) was not significantly affected.. Incorrect EVD placement is a strong and independent risk factor for puncture channel bleeding in patients with aSAH, whereas antiplatelet and anticoagulation therapy did not significantly influence bleeding risk. Although PCB was not associated with cognitive impairment, it was independently associated withworse functional outcome after adjustment for confounders. These findings highlight the critical importance of accurate catheter trajectory in reducing procedure-related complications and improving overall outcome in neurovascular care.
- 8 May 2026
- Vol. 150, 112077
Influence of the correct placement of external ventricular drainage on puncture channel bleeding in patients with aneurysmal subarachnoid hemorrhage.
While ventriculostomy-associated hemorrhages are well-documented in spontaneous subarachnoid hemorrhage (SAH), the impact of external ventricular drainage (EVD) placement accuracy on puncture channel bleeding (PCB) remains underexplored. This study investigates whether incorrect EVD trajectory is associated with increased PCB risk in aneurysmal SAH (aSAH) patients and evaluates the influence of peri-interventional antiplatelet and anticoagulation therapy on these events. We analyzed 127 patients with aSAH who underwent EVD placement and aneurysm treatment between September 2021 and June 2025 from our prospectively maintained registry. EVD positioning was classified as correct (ipsilateral intraventricular) or incorrect (e.g., contralateral or intraparenchymal). PCB was defined as hemorrhage along the catheter tract on post-procedural CT. Data on antiplatelet/anticoagulant use and clinical outcomes were collected. Functional and cognitive outcomes were assessed using the modified Rankin Scale (mRS) and Montreal Cognitive Assessment (MoCA), respectively. PCB occurred in 20% of patients. Incorrect EVD placement was strongly associated with PCB, occurring in 56% of malpositioned catheters compared with 15% of correctly positioned catheters (p < 0.001). In multivariable logistic regression, incorrect EVD placement remained the only independent predictor of PCB (OR 7.8, 95% CI 2.45-26.35; p < 0.001). Neither pre-admission antiplatelet or anticoagulation therapy nor peri-interventional antiplatelet therapy was significantly associated with PCB (all p = 0.5). In univariate analysis, functional outcome at discharge and at 3 months did not significantly differ between groups (p = 0.43 and p = 0.28, respectively). However, in multivariable analysis adjusting for age and clinical severity, PCB was independently associated with a lower likelihood of favorable functional outcome both at discharge (OR 0.19, 95% CI 0.04-0.70; p = 0.02) and at 3 months (OR 0.10, 95% CI 0.01-0.75; p = 0.03). Cognitive outcome (MoCA) was not significantly affected.. Incorrect EVD placement is a strong and independent risk factor for puncture channel bleeding in patients with aSAH, whereas antiplatelet and anticoagulation therapy did not significantly influence bleeding risk. Although PCB was not associated with cognitive impairment, it was independently associated withworse functional outcome after adjustment for confounders. These findings highlight the critical importance of accurate catheter trajectory in reducing procedure-related complications and improving overall outcome in neurovascular care.
- Open Access
- 2 May 2026
- Published by Elsevier in Brain and Spine
- Vol. 6
Incidence, risk factors, clinical and cognitive impact of secondary hemorrhage after spontaneous aneurysmal subarachnoid hemorrhage
- 2 May 2026
- Published by Elsevier in Brain and Spine
- Vol. 6
Open AccessIncidence, risk factors, clinical and cognitive impact of secondary hemorrhage after spontaneous aneurysmal subarachnoid hemorrhage
- Open Access
- 15 October 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Low tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry
Purpose: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. Methods: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. Results: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models. Conclusion: The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.
- 15 October 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Open AccessLow tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry
Purpose: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. Methods: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. Results: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models. Conclusion: The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (3) , 555-565
Case fatality and functional outcome after spontaneous subarachnoid haemorrhage: A systematic review and meta-analysis of time trends and regional variations in population-based studies
Introduction: A previous systematic review of population-based studies from 1973 to 2002 found a decrease in case fatality for spontaneous subarachnoid haemorrhage, but could not find a sufficient number of studies to assess changes in functional outcome. Since then, treatment has advanced distinctly. We assessed whether case fatality has decreased further and whether functional outcome has improved. Patients and methods: We searched PubMed and Web of Science for new population-based studies using the same criteria as in our previous systematic review. We assessed changes in case fatality and functional outcome over time using linear regression. Results: We included 24 new studies with 827 patients and analysed 9542 patients described in 62 study periods between 1973 and 2017. Case fatality decreased by 0.3% (95% CI: −0.7 to 0.1) per year. In a sensitivity analysis excluding studies that did not provide 1-month outcome and outliers, the age and sex-adjusted decrease was 0.1% per year (95% CI: −0.9 to 0.6). The mean case fatality rate decreased from 47% (95% CI: 31–63) in the 1970s to 35% (95% CI: 30–39) in the 1990s, and remained stable in the 2000s (34%; 95% CI: 27–41) and 2010s (38%; 95% CI: 15–60). In 15 studies, the mean proportion of patients living independently increased by 0.2% per year (95%CI: −0.7 to 1.1) and the mean was 45% (95% CI: 39–50) in six studies that reported outcome after 12 months. Discussion and conclusion: From 1973 to 2017, the case-fatality rate of spontaneous subarachnoid haemorrhage declined overall by 13.5%, but remained stable over the last two decades. The data on time trends in functional outcome were inconclusive.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (3) , 555-565
Case fatality and functional outcome after spontaneous subarachnoid haemorrhage: A systematic review and meta-analysis of time trends and regional variations in population-based studies
Introduction: A previous systematic review of population-based studies from 1973 to 2002 found a decrease in case fatality for spontaneous subarachnoid haemorrhage, but could not find a sufficient number of studies to assess changes in functional outcome. Since then, treatment has advanced distinctly. We assessed whether case fatality has decreased further and whether functional outcome has improved. Patients and methods: We searched PubMed and Web of Science for new population-based studies using the same criteria as in our previous systematic review. We assessed changes in case fatality and functional outcome over time using linear regression. Results: We included 24 new studies with 827 patients and analysed 9542 patients described in 62 study periods between 1973 and 2017. Case fatality decreased by 0.3% (95% CI: −0.7 to 0.1) per year. In a sensitivity analysis excluding studies that did not provide 1-month outcome and outliers, the age and sex-adjusted decrease was 0.1% per year (95% CI: −0.9 to 0.6). The mean case fatality rate decreased from 47% (95% CI: 31–63) in the 1970s to 35% (95% CI: 30–39) in the 1990s, and remained stable in the 2000s (34%; 95% CI: 27–41) and 2010s (38%; 95% CI: 15–60). In 15 studies, the mean proportion of patients living independently increased by 0.2% per year (95%CI: −0.7 to 1.1) and the mean was 45% (95% CI: 39–50) in six studies that reported outcome after 12 months. Discussion and conclusion: From 1973 to 2017, the case-fatality rate of spontaneous subarachnoid haemorrhage declined overall by 13.5%, but remained stable over the last two decades. The data on time trends in functional outcome were inconclusive.
- Open Access
- 17 October 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (1) , 626
Correction to: Synergistic effects of vagus nerve stimulation and antiseizure medication
- 17 October 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (1) , 626
Open AccessCorrection to: Synergistic effects of vagus nerve stimulation and antiseizure medication
- Open Access
- 27 June 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (10) , 4978-4984
Synergistic effects of vagus nerve stimulation and antiseizure medication
Introduction: Vagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures. Until now, favorable combinations of different groups of antiseizure medication (ASM) and VNS have not been sufficiently addressed. The aim of this study was to identify the synergistic effects between VNS and different ASMs. Methods: We performed an observational study of patients with epilepsy who were implanted with VNS and had a stable ASM therapy during the first 2 years after the VNS implantation. Data were collected from the Mainz Epilepsy Registry. The efficacy of VNS depending on the concomitantly used ASM group/individual ASMs was assessed by quantifying the responder rate (≥ 50% seizure reduction compared to the time of VNS implantation) and seizure freedom (absence of seizures during the last 6 months of the observation period). Results: One hundred fifty one patients (mean age 45.2 ± 17.0 years, 78 females) were included in the study. Regardless of the used ASM, the responder rate in the whole cohort was 50.3% and the seizure freedom was 13.9%. Multiple regression analysis showed that combination of VNS with synaptic vesicle glycoprotein (SV2A) modulators (responder rate 64.0%, seizure freedom 19.8%) or slow sodium channel inhibitors (responder rate 61.8%, seizure freedom 19.7%) was associated with a statistically significant better responder rate and seizure freedom than combinations of VNS and ASM with other mechanism of action. Within these ASM groups, brivaracetam showed a more favorable effect than levetiracetam, whereas lacosamide and eslicarbazepine were comparable in their effects. Conclusion: Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.
- 27 June 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (10) , 4978-4984
Open AccessSynergistic effects of vagus nerve stimulation and antiseizure medication
Introduction: Vagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures. Until now, favorable combinations of different groups of antiseizure medication (ASM) and VNS have not been sufficiently addressed. The aim of this study was to identify the synergistic effects between VNS and different ASMs. Methods: We performed an observational study of patients with epilepsy who were implanted with VNS and had a stable ASM therapy during the first 2 years after the VNS implantation. Data were collected from the Mainz Epilepsy Registry. The efficacy of VNS depending on the concomitantly used ASM group/individual ASMs was assessed by quantifying the responder rate (≥ 50% seizure reduction compared to the time of VNS implantation) and seizure freedom (absence of seizures during the last 6 months of the observation period). Results: One hundred fifty one patients (mean age 45.2 ± 17.0 years, 78 females) were included in the study. Regardless of the used ASM, the responder rate in the whole cohort was 50.3% and the seizure freedom was 13.9%. Multiple regression analysis showed that combination of VNS with synaptic vesicle glycoprotein (SV2A) modulators (responder rate 64.0%, seizure freedom 19.8%) or slow sodium channel inhibitors (responder rate 61.8%, seizure freedom 19.7%) was associated with a statistically significant better responder rate and seizure freedom than combinations of VNS and ASM with other mechanism of action. Within these ASM groups, brivaracetam showed a more favorable effect than levetiracetam, whereas lacosamide and eslicarbazepine were comparable in their effects. Conclusion: Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.
- 1 March 2023
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 8 (1) , 320-327
Validation of the German version of the subarachnoid haemorrhage outcome tool (SAHOT)
Objective: The subarachnoid haemorrhage (SAH) outcome tool (SAHOT) is the first SAH-specific patient reported outcome measure, and was developed in the UK. We aimed to validate the SAHOT outside the UK, and therefore endeavored to adapt the SAHOT into German and to test its psychometric properties. Methods: We adapted and pilot tested the German version. We applied the SAHOT, Quality of Life after Brain Injury, Hospital Anxiety and Depression Scale, and EuroQol questionnaires in a cohort of 89 patients with spontaneous SAH after discharge. We assessed internal consistency by Cronbach’s α, test-retest reliability by intraclass correlation, and validity by Pearson correlations with established measures. Sensitivity to change was evaluated following neurorehabilitation by effect sizes. Results: The translation of SAHOT resulted in a German version that is semantically and conceptually equivalent to the English version. Internal consistency was good regarding the physical domain (α = 0.83) and excellent for the other domains (α = 0.92–0.93). Test–retest reliability indicated a high level of stability with an intraclass correlation of 0.85 (95% CI: 0.83–0.86). All domains correlated moderately or strongly with established measures (r = 0.41–0.74; p < 0.01). SAHOT total scores showed moderate sensitivity to change (Cohen’s d = −0.68), while mRS and GOSE showed no significant sensitivity to change. Conclusion: The SAHOT can be adapted to other health care systems and societies than the UK. The German version of the SAHOT is a reliable and valid instrument, and can be used in future clinical studies and individual assessment after spontaneous SAH.
- 1 March 2023
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 8 (1) , 320-327
Validation of the German version of the subarachnoid haemorrhage outcome tool (SAHOT)
Objective: The subarachnoid haemorrhage (SAH) outcome tool (SAHOT) is the first SAH-specific patient reported outcome measure, and was developed in the UK. We aimed to validate the SAHOT outside the UK, and therefore endeavored to adapt the SAHOT into German and to test its psychometric properties. Methods: We adapted and pilot tested the German version. We applied the SAHOT, Quality of Life after Brain Injury, Hospital Anxiety and Depression Scale, and EuroQol questionnaires in a cohort of 89 patients with spontaneous SAH after discharge. We assessed internal consistency by Cronbach’s α, test-retest reliability by intraclass correlation, and validity by Pearson correlations with established measures. Sensitivity to change was evaluated following neurorehabilitation by effect sizes. Results: The translation of SAHOT resulted in a German version that is semantically and conceptually equivalent to the English version. Internal consistency was good regarding the physical domain (α = 0.83) and excellent for the other domains (α = 0.92–0.93). Test–retest reliability indicated a high level of stability with an intraclass correlation of 0.85 (95% CI: 0.83–0.86). All domains correlated moderately or strongly with established measures (r = 0.41–0.74; p < 0.01). SAHOT total scores showed moderate sensitivity to change (Cohen’s d = −0.68), while mRS and GOSE showed no significant sensitivity to change. Conclusion: The SAHOT can be adapted to other health care systems and societies than the UK. The German version of the SAHOT is a reliable and valid instrument, and can be used in future clinical studies and individual assessment after spontaneous SAH.